Clinical trial
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
Abstract
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleMDMA
Chemsex drugs: More than ghb, mephedrone and methamphetamine?
ArticleKetamine
Midazolam-Ketamine (MK) Versus Propofol-Ketamine (PK) for Pediatric Burn Patients Undergoing Dressing Changes: A Non-Randomized Cross-Over Clinical Trial.
ArticleKetamine